Mortality from cirrhosis: Lack of progress over the last 35 years

Gut

Volumn 54, Issue 11, 2005, Pages 1523-1526

  Gluud, C ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; RECOMBINANT INTERFERON; RIBAVIRIN; TERLIPRESSIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE CLASSIFICATION; ENDOSCOPIC SURGERY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL ERROR; MORTALITY; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

ENGLAND; EPIDEMIOLOGIC METHODS; HUMANS; LIVER CIRRHOSIS; MORTALITY;

EID: 27444434718     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.072876     Document Type: Review

References (48)

1. Roberts SE, Goldacre MJ, Yeates D. Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 2005;54:1615-21.
2. Neuberger J. Developments in liver transplantation. Gut 2004;53:759-68.
3. Samonakis DN, Triantos CK, Thalheimer U, et al. Management of portal hypertension. Postgrad Med J 2004;80:634-41.
4. de Franchis R. Evolving consensus in portal hypertension. Report or the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76.
5. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-61.
6. Pawlotsky JM, McHutchison JG. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls, Summary of an AASLD hepatitis single topic conference, Chicago, IL, 27 February-1 March 2003. Hepatology 2004;39:554-67.
7. Soares-Weiser K, Brezis M, Tur-Kaspa R, et al. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. The Cochrane Database of Systematic Reviews 2002, issue 2. Oxford: Update Software, 2002, art. No CD002907.
8. Soares-Weiser K, Brezis M, Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotics. The Cochrane Database of Systematic Reviews 2001, issue 3. Oxford: Update Software, 2001, art. No CD002232.
9. Thalheimer U, Triantos CK, Samonakis DN, et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005;54:556-63.
10. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171-80.
11. Nielsen SD, Gluud C. Physicians' information about alcohol problems at hospitalisation of alcohol misusers. Alcohol Alcohol 1992;27:659-65.
12. Nielsen SD, Storgaard H, Moesgaard F, et al. Prevalence of alcohol problems among adult somatic in-patients of a Copenhagen hospital. Alcohol Alcohol 1994;29:583-90.
13. Storgaard H, Nielsen SD, Gluud C. The validity of the Michigan Alcoholism Screening Test (MAST) - a review. Alcohol Alcohol 1994;29:493-502.
14. McCusker MT, Basquille J, Khwaja M, et al. Hazardous and harmful drinking: a comparison of the AUDIT and CAGE screening questionnaires. QJM 2002;95:591-5.
15. Vass A. Rates of liver cirrhosis rise in England, fall in Europe. BMJ 2001;323:1388.
16. Saunders JB, Walters JR, Davies AP, et al. A 20-year prospective study of cirrhosis. BMJ Clin Res Ed 1981;282:263-6.
17. Sørensen HT, Thulstrup AM, Mellemkjar L, et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. J Clin Epidemiol 2003;56:88-93.
18. Vestberg K, Thulstrup AM, Sorensen HT, et al. Data quality of administratively collected hospital discharge data for liver cirrhosis epidemiology. J Med Syst 1997;21:11-20.
19. Poynard T, Naveau S, Doffoel M, et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. J Hepatol 1999;30:1130-7.
20. Khuroo MS, Khuroo NS, Farahat KL, et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005;21:347-61.
21. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. The Cochrane Database of Systematic Reviews 2003, issue 1. Oxford: Update Software, 2003, art. No CD002147.
22. D'Amico G, Pagliaro L, Pietrosi G, et al. Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients. The Cochrane Database of Systematic Reviews 2002, Issue 1. Oxford: Update Software, 2002, art. No CD002233.
23. de la Pena J, Brullet E, Sanchez-Hernandez E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005;41:572-8.
24. Sauer P, Hansmann J, Richter GM, et al. Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial, Endoscopy 2002;34:690-7.
25. Escorsell A, Banares R, Garcia-Pagan JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002;35:385-92.
26. Saab S, Nieto JM, Ly D, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. The Cochrane Database of Systematic Reviews 2004, issue 3. Oxford: Update Software, 2004, art. No CD004889.
27. Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin Liver Dis 2005;25:155-61.
28. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
29. Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C - an updated systematic Cochrane review on 72 randomised clinical trials with 9991 patients. J Hepatol 2005;42(suppl 2):201.
30. Gluud LL, Kürstein P, Kjellberg J, et al. The size of the gap between research evidence and clinical practice: questionnaire survey on treatment of patients with liver disease. 12th Cochrane Colloquium, Ottawa, Canada, 2-6 October 2004: abstract 129).
31. Kürstein P, Gluud LL, Willemann M, et al. Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews. J Hepatol 2005 (in press).
32. Gluud C, Als-Nielsen B, D'Amico G, et al. The Cochrane Hepato-Biliary Group. About The Cochrane Collaboration. Collaborative Review Groups (CRGs)) 2005, Issue 2. Oxford: Update Software, 2005, art. No, LIVER.
33. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdoses. The Cochrane Database of Systematic Reviews 2002, issue 3. Oxford: Update Software, 2002, art. No CD003328.
34. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. The Cochrane Database of Systematic Reviews 2003, issue 1. Oxford: Update Software, 2003, art. No CD003045.
35. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. The Cochrane Database of Systematic Reviews 2005, issue 2. Oxford: Update Software, 2005, art. No CD002148.
36. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. The Cochrane Database of Systematic Reviews 2001, issue 4. Oxford: Update Software, 2001, art. No CD002800.
37. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. The Cochrane Database of Systematic Reviews 2001, issue 4. Oxford: Update Software, 2001, art. No CD002235.
38. Gluud C, Nikolova D. Quality assessment of reports on clinical trials in Journal of Hepatology. J Hepatol 1998;29:321-7.
39. Kjærgard LL, Nikolova D, Gluud C. Randomized clinical trials in hepatology-predictors of quality. Hepatology 1999;30:1134-8.
40. Kjaergard LL, Frederiksen S, Gluud C. Validity of randomized clinical trials in Gastroenterology from 1964-2000. Gastroenterology 2002;122:1157-60.
41. Kjaergard LL, Gluud C. Funding, disease area, and internal validity of hepato-biliary randomized clinical trials. Am J Gastroenterol 2002;97:2708-13.
42. Gluud C. Trials and errors in clinical research. Lancet 1999;354:siv59.
43. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982-9.
44. Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomised drug trials. A reflection of treatment effect or adverse events? JAMA 2003;290:921-8.
45. House of Commons Health Committee. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004-05. 2005. http://www.publications. parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 23 August 2005).
46. Krleza-Jeric K, Chan A-W, Dickersin K, et al. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (Part 1). BMJ 2005;330:956-8.
47. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 (updated March 2005), The Cochrane Library, issue 2. Chichester, UK: John Wiley and Sons, Ltd, 2005.
48. Patsopoulos NA, Analatos AA, Ioannidis JP. Relative citation impact of various study designs in the health sciences. JAMA 2005;293:2362-6.